Blackstone Royalties

Blackstone Life Sciences is a specialized investment platform within Blackstone that provides flexible funding solutions across the life sciences sector. Formed through the acquisition of Clarus in 2018, the group focuses on three main investment strategies: strategic collaborations with major pharmaceutical companies (R&D partnering), late-stage venture capital, and royalty acquisitions. The firm manages billions of dollars in assets and provides the necessary capital to bring promising new medicines and medical technologies to market. By acquiring royalties or co-funding Phase 3 development programs, Blackstone Life Sciences helps accelerate the delivery of innovative treatments to patients while generating returns for its investors.